Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
Investing.com -- INVO Fertility, Inc. (NASDAQ:IVF) stock surged 13% after the company announced it received a notice of allowance on a new patent for a modified version of its proprietary INVOcell device. The new patent extends intellectual property protection through 2040.
The United States Patent and Trademark Office (USPTO) issued the Notice of Allowance for a patent application titled "Intravaginal Culture Incubation Container and Method" dated June 17, 2025. The modified design reflects feedback from leading embryologists to simplify the device by creating a singular main chamber without a separate microchamber.
INVOcell is the world’s first FDA-cleared intravaginal culture system that enables fertilization and early embryo development to occur within a woman’s body rather than in a laboratory setting. The device was originally granted FDA clearance in 2015, with an updated clearance in 2023 that increased the incubation period from 3 days to 5 days.
According to the company, the INVOcell procedure involves placing eggs and sperm in the thumb-sized device, which is then inserted into the vaginal cavity for a 5-day incubation period. After incubation, embryos are transferred to the uterus, with any remaining embryos available for freezing.
Steve Shum, CEO of INVO Fertility, stated that the receipt of the new patent "expands our intellectual property protection to this innovative approach, which delivers success rates comparable to traditional IVF, helping to make parenthood more accessible and inclusive for those facing infertility challenges worldwide."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.